Agilent (A) 10-K 21 Dec 09 2009 FY Annual report Financial data

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS (USD $)
In Millions, except Share data	12 Months Ended Oct. 31, 2009	12 Months Ended Oct. 31, 2008	12 Months Ended Oct. 31, 2007
Net revenue:
Products	$3,566	$4,804	$4,505
Services and other	915	970	915
Total net revenue	4,481	5,774	5,420
Costs and expenses:
Cost of products	1,692	2,030	1,928
Cost of services and other	497	548	523
Total costs	2,189	2,578	2,451
Research and development	642	704	685
Selling, general and administrative	1,603	1,697	1,700
Total costs and expenses	4,434	4,979	4,836
Income from operations	47	795	584
Interest income	29	113	172
Interest expense	(88)	(123)	(91)
Other income (expense), net	19	30	5
Income before taxes	7	815	670
Provision for income taxes	38	122	32
Net income (loss)	($31)	$693	$638
Net income (loss) per share - Basic:	-0.09	1.91	1.62
Net income (loss) per share - Diluted:	-0.09	1.87	1.57
Weighted average shares used in computing net income (loss) per share:
Basic	346	363	394
Diluted	346	371	406

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET (USD $)
In Millions	Oct. 31, 2009	Oct. 31, 2008
Current assets:
Cash and cash equivalents	$2,479	$1,405
Short-term investments	14	24
Accounts receivable, net	595	770
Inventory	552	646
Other current assets	321	337
Total current assets	3,961	3,182
Property, plant and equipment, net	845	824
Goodwill	655	646
Other intangible assets, net	167	228
Restricted cash and cash equivalents	1,566	1,582
Long-term investments	163	206
Other assets	255	339
Total assets	7,612	7,007
Current liabilities:
Accounts payable	307	308
Employee compensation and benefits	336	409
Deferred revenue	285	280
Income and other taxes payable	26	128
Other accrued liabilities	169	205
Total current liabilities	1,123	1,330
Long-term debt	1,516	1,514
Senior notes	1,388	611
Retirement and post-retirement benefits	498	324
Other long-term liabilities	581	669
Total liabilities	5,106	4,448
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 566 million shares at October 31, 2009 and 561 million shares at October 31, 2008 issued	6	6
Treasury stock at cost; 220 million shares at October 31, 2009 and 211 million shares at October 31, 2008	(7,627)	(7,470)
Additional paid-in-capital	7,552	7,410
Retained earnings	2,760	2,791
Accumulated other comprehensive loss	(185)	(178)
Total stockholders' equity	2,506	2,559
Total liabilities and stockholders' equity	$7,612	$7,007

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
In Millions	12 Months Ended Oct. 31, 2009	12 Months Ended Oct. 31, 2008	12 Months Ended Oct. 31, 2007
Cash flows from operating activities:
Net income	($31)	$693	$638
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	162	201	191
Share-based compensation	71	82	139
Deferred taxes	28	(53)	(134)
Excess and obsolete inventory-related charges	54	24	21
Translation gain from liquidation of a subsidiary	0	(25)	0
Non-cash restructuring and asset impairment charges	39	8	8
Net (gain) loss on sale of investments	0	4	(2)
Net (gain) loss on sale of assets and divestitures	(6)	2	(13)
Net Pension Curtailment And Settlement Gains	(16)	0	(1)
Other	2	(1)	2
Changes in assets and liabilities:
Accounts receivable, net	193	(44)	22
Inventory	47	(14)	(21)
Accounts payable	(7)	(21)	(13)
Employee compensation and benefits	(86)	(10)	13
Income taxes and other taxes payable	(105)	45	132
Interest rate swap proceeds	43	0	0
Other assets and liabilities	20	(135)	(13)
Net cash provided by operating activities	408	756	969
Cash flows from investing activities:
Investments in property, plant and equipment	(128)	(154)	(154)
Proceeds from the sale of property, plant and equipment	1	14	12
Proceeds from divestitures, net	45	0	14
Purchase of investment securities	(30)	(256)	0
Proceeds from the sale of investment securities	94	150	13
Change in restricted cash, cash equivalents and investments, net	16	33	3
Purchase of minority interest	(10)	(14)	0
Acquisitions of businesses and intangible assets, net of cash acquired	(2)	(172)	(344)
Net cash used in investing activities	(14)	(399)	(456)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	71	211	375
Treasury stock repurchases	(157)	(1,001)	(1,944)
Proceeds from credit facility	325	510	0
Repayment of credit facility	(325)	(510)	0
Proceeds from long-term debt and senior notes	748	16	598
Debt issuance costs	(5)	0	(5)
Payment of debt	0	0	(4)
Net cash provided by (used in) financing activities	657	(774)	(980)
Effect of exchange rate movements	23	(4)	31
Net increase (decrease) in cash and cash equivalents	1,074	(421)	(436)
Cash and cash equivalents at beginning of year	1,405	1,826	2,262
Cash and cash equivalents at end of year	$2,479	$1,405	$1,826

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)
In Millions, except Share data in Thousands	Common Stock	Additional paid in capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income/(Loss)	Total
Balance - shares at Oct. 31, 2006	535,109		(126,732)
Balance - value at Oct. 31, 2006	$5	$6,605	($4,525)	$1,534	$29	$3,648
Net income	0	0	0	638	0	638
Change in unrealized gain on investments	0	0	0	0	23	23
Change in unrealized gain on derivative instruments	0	0	0	0	(4)	(4)
Change in foreign currency translation	0	0	0	0	150	150
Change in minimum pension liability	0	0	0	0	112	112
Amortization of non US pension plan costs	0	0	0	0	2	2
Deferred taxes, primarily related to currency translation and unrealized gain on investments	0	0	0	0	(31)	(31)
Adjustment to initially apply amendment to ASC 715, "Compensation - Retirement Benefits", including tax impact	0	0	0	0	127	127
Share based awards issued, shares	16,013		0
Share based awards issued, amount	1	373	0	0	0	374
Repurchase of common stock, amount	0	0	(1,944)	0	0	(1,944)
Repurchase of common stock, shares	0		(54,009)
Share-based compensation	0	139	0	0	0	139
Balance - shares at Oct. 31, 2007	551,122		(180,741)
Balance - Value at Oct. 31, 2007	6	7,117	(6,469)	2,172	408	3,234
Net income	0	0	0	693	0	693
Change in unrealized gain on investments	0	0	0	0	(40)	(40)
Change in unrealized gain on derivative instruments	0	0	0	0	(26)	(26)
Translation gain reclassified into earnings related to liquidation of a subsidiary	0	0	0	0	(25)	(25)
Change in foreign currency translation	0	0	0	0	(100)	(100)
Deferred taxes, primarily related to currency translation and unrealized gain on investments	0	0	0	0	13	13
Change in deferred net pension costs net loss, including tax impact					(409)	(409)
Change in deferred net pension costs, net prior service credit	0	0	0	0	1	1
Adjustment to initially apply amendment to ASC 740, "Income Taxes"	0	0	0	(74)	0	(74)
Share based awards issued, shares	9,545		0
Share based awards issued, amount	0	211	0	0	0	211
Repurchase of common stock, amount	0	0	(1,001)	0	0	(1,001)
Repurchase of common stock, shares	0		(30,081)
Share-based compensation	0	82	0	0	0	82
Balance - shares at Oct. 31, 2008	560,667		(210,822)
Balance - Value at Oct. 31, 2008	6	7,410	(7,470)	2,791	(178)	2,559
Net income	0	0	0	(31)	0	(31)
Change in unrealized gain on investments	0	0	0	0	6	6
Change in unrealized gain on derivative instruments	0	0	0	0	1	1
Losses reclassified into earnings related to derivative instruments	0	0	0	0	23	23
Change in foreign currency translation	0	0	0	0	157	157
Deferred taxes, primarily related to currency translation and unrealized gain on investments	0	0	0	0	(6)	(6)
Change in deferred net pension costs net loss, including tax impact	0	0	0	0	(287)	(287)
Change in deferred net pension costs, net prior service credit	0	0	0	0	99	99
Share based awards issued, shares	5,400		0
Share based awards issued, amount	0	71	0	0	0	71
Repurchase of common stock, amount	0	0	(157)	0	0	(157)
Repurchase of common stock, shares	0		(9,097)
Share-based compensation	0	71	0	0	0	71
Balance - shares at Oct. 31, 2009	566,067		(219,919)
Balance - Value at Oct. 31, 2009	$6	$7,552	($7,627)	$2,760	($185)	$2,506

OVERVIEW AND SUMMARY OF SIGNIFI

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Overview And Summary Of Significant Accounting Policies	1. OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. (we, Agilent or the company), incorporated in Delaware in May 1999, is a measurement company, providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. Proposed Acquisition of Varian, Inc. On July26, 2009, Agilent, Varian,Inc. (Varian), and Cobalt Acquisition Corp., a direct, wholly-owned subsidiary of Agilent, entered into an Agreement and Plan of Merger (the Merger Agreement).Pursuant to the terms of the Merger Agreement, Varian would become a wholly-owned subsidiary of Agilent. Varian is a leading worldwide supplier of scientific instrumentation and associated consumables for life science and applied market applications. The estimated $1.5 billion total purchase price of Varian includes $52 cash per share of Varians common stock, the cashing out of in the money stock options (after acceleration) and assumed debt. The transaction has been approved by shareholders of Varian and is expected to be completed after achieving customary closing conditions and regulatory approvals. We may finance the purchase price of Varian using a portion of the proceeds from our September 2009 offering of senior notes and other existing cash. Revisions to Financial Statement Presentation. We have revised our consolidated balance sheet as of October 31, 2008 to correct an error in the classification of deferred tax assets and liabilities.This revision does not impact the consolidated statement of operations or the consolidated statement of cash flows for any period.During the April 30, 2009 quarter-end process, we noted that the October 31, 2008 U.S. deferred tax valuation allowances and certain deferred tax assets/deferred tax liabilities were misclassified on the balance sheet as a result of improperly applying the jurisdictional netting rules. We have therefore revised our balance sheet as of October 31, 2008 by decreasing other long-term liabilities by $435 million and decreasing other long-term assets by $404 million, decreasing other current assets by $26 million and increasing other accrued liabilities by $5 million. Basis of presentation. The accompanying financial data has been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October31. Unless otherwise stated, all years and dates refer to our fiscal year. Management is responsible for the fair presentation of the accompanying consolidated financial statements, prepared in accordance with U.S. GAAP, and has full responsibility for their integrity and accuracy. In the opinion of management, the accompanying consolidated financial statements contain all adjustments necessary to present fairly our consolidated balance sheet, statement of operations, statement of cash flows and statement of stockholders equity for all periods presented. Reclassifications. Certain prior year financial statement amounts have been reclassified to conform to the c

NEW ACCOUNTING PRONOUNCEMENTS

NEW ACCOUNTING PRONOUNCEMENTS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
New Accounting Pronouncements	2. NEW ACCOUNTING PRONOUNCEMENTS In September 2006, the Financial Accounting Standards Board (FASB) issued guidance onmeasurements of fair value. The guidance defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. The guidance does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In February2008, the FASB issued authoritative guidance which allowed for the delay of the effective date of the authoritative guidance for nonfinancial assets and nonfinancial liabilities, except for certain items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Effective November 1, 2008, we adopted the measurement and disclosure requirements related to financial assets and financial liabilities. The adoption of theguidance for financial assets and financial liabilities did not have a material impact on the companys results of operations or the fair values of its financial assets and liabilities. We arerequired to apply the provisions to nonfinancial assets and nonfinancial liabilities as of November1, 2009 and do not expect it to have a material impact on our consolidated financial statements. On October 31, 2007, the company adopted FASBs guidance on defined benefit pension and other postretirement plans. This authoritative guidance requires recognition of the overfunded or underfunded status of each plan as an asset or liability in the consolidated balance sheet with the offsetting change in that funded status to accumulated other comprehensive income. Upon adoption, this guidance required immediate recognition in accumulated other comprehensive income of actuarial gains/losses and prior service costs/benefits--both of which were previously unrecognized. Additional minimum pension liabilities and related intangible assets are eliminated upon adoption of the new standard. As required by the guidance, the company has moved the measurement date for our non-U.S. plans from September 30 to October 31 effective October 31, 2009.The adoption of the measurement provisions did not have a material impact on our consolidation financial statements. In December 2007, the FASB issued amendments to the guidance for business combinations.The revised guidance provides the recognition and measurement requirements of identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires additional disclosures to enable users of the financial statements to evaluate the nature and financial effects of the business combination. This guidance is effective beginning November 1, 2009, at which time we will change our accounting treatment for business combinations. As a result of adopting the amended guidance on November 1, 2009, we did not have a material impact to our consolidated financial statements. In December 2007, the FASB issued new guidance on non-controlling interests in consolidated financial statements.The guidance requires that ownership inte

SHARE BASED COMPENSATION

SHARE BASED COMPENSATION
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Share-Based Compensation	3. SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the revised accounting guidancewhich requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our ESPP and performance share awards granted to selected members of our senior management under the LTPP based on estimated fair values. Description of Share-Based Plans Employee stock purchase plan. Effective November1, 2000, we adopted the ESPP.Prior to November 1, 2008, under the provisions of the ESPP, eligible employees could contribute up to ten percent of their base compensation to purchase shares of our common stock at 85percent of the lower of the fair market value at the entry date or the purchase date of each offering period, as defined by the ESPP.Effective November 1, 2008, the Compensation Committee of Board of Directors approved a change to our ESPP that eliminated the look back period. The ESPP will continue to allow eligible employees to purchase shares of our common stock at 85 percent of the purchase price, but only uses the purchase date to establish the fair market value. As of October31, 2009, the number of shares of common stock authorized and available for issuance under our ESPP was 26,710,768. Shares authorized for issuance in connection with the ESPP are subject to an automatic annual increase of the lesser of one percent of the outstanding shares of common stock of Agilent on November 1, or an amount determined by the Compensation Committee of our Board of Directors.Under the terms of the ESPP, in no event shall the number of shares issued under the ESPP exceed 75million shares. Incentive compensation plans.On November 19, 2008 and March 11, 2009, the Compensation Committee of Board of Directors and the stockholders, respectively, approved the Agilent Technologies,Inc. 2009 Stock Plan (the "2009 Stock Plan") to replace the Companys 1999 Stock Plan and 1999 Stock Non-Employee Director Stock Plan and subsequently reserved 25,000,000 shares of Company common stock that may be issued under the 2009 Plan, plus any shares forfeited or cancelled under the 1999 Stock Plan. The 2009 Stock Plan provides for the grant of awards in the form of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units (RSUs), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards.The 2009 Plan has a term of ten years. As of October 31, 2009, 25,872,956 shares were available for future awards under the 2009 Stock Plan. Stock options granted under the 2009 Stock Plans may be either "incentive stock options", as defined in Section422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25percent per year over a period of four years from the date of grant and generally have a maximum contractual term of ten years.The exercise price for stock options is generally not less than 100percent of the fair market value of our common stock o

PROVISION

PROVISION (BENEFIT) FOR INCOME TAXES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Provision (Benefit) For Income Taxes	4.PROVISION FOR INCOME TAXES The provision for income taxes from operations is comprised of: Years Ended October 31, 2009 2008 2007 (in millions) U.S. federal taxes from operations: Current $ (20 ) $ 39 $ 71 Deferred 26 (33 ) (127 ) Non-U.S. taxes from operations: Current 20 114 91 Deferred 6 (3 ) (5 ) State taxes from operations, net of federal benefit: Current 10 22 3 Deferred (4 ) (17 ) (1 ) Total provision from operations $ 38 $ 122 $ 32 The income tax provisions do not reflect potential future tax savings resulting from excess deductions associated with our various share-based award plans. The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: Years Ended October 31, 2009 2008 Deferred Tax Assets Deferred Tax Liabilities Deferred Tax Assets Deferred Tax Liabilities (in millions) Inventory $ 76 $ $ 61 $ Property, plant and equipment 19 72 19 86 Warranty reserves 11 1 11 1 Retiree medical benefits 44 1 42 1 Other retirement benefits 98 50 105 119 Employee benefits, other than retirement 192 204 Net operating loss and credit carryforwards 239 307 Unremitted earnings of foreign subsidiaries 53 72 Share-based compensation 54 51 Deferred revenue 284 253 Other 50 10 67 7 Subtotal 1,067 187 1,120 286 Tax valuation allowance (684 ) (621 ) Total deferred tax assets or deferred taxliabilities $ 383 $ 187 $ 499 $ 286 The breakdown between current and long-term deferred tax assets and deferred tax liabilities was as follows for the years 2009 and 2008: Years Ended October 31, (in millions) 2009 2008 Current deferred tax assets (included withinother current assets) $ 139 $ 132 Long-term deferred tax assets (included within other assets) 47 95 Current deferred tax liabilities (included within income and other taxes payable) (3 ) (11 ) Long-term deferred tax liabilities (included within other long-term liabilities) 13 (3 ) Total $ 196 $ 213 The consolidated balance sheet reflects the allocation of the valuation allowance based on the pro-rata portion of gross current and non-current deferred tax assets in each jurisdiction where a valuation allowance is required. During 2003, we established valuation allowances for the deferred tax assets of the U.S. and certain entities in foreign jurisdictions. The valuation allowances were determined in accordance with the provisions of the authoritative guidance which require an assessment of both posit

NET INCOME PER SHARE

NET INCOME PER SHARE
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Net Income (Loss) Per Share	5.NET INCOME (LOSS) PER SHARE The following is a reconciliation of the numerators and denominators of the basic and diluted net income (loss) per share computations for the periods presented below. As a result of the companys net loss in 2009, the computation of diluted net loss per share for 2009 excludes the diluted impact of all common stock equivalents outstanding. Years Ended October 31, 2009 2008 2007 (in millions) Numerator: Net income (loss) $(31) $693 $638 Denominators: Basic weighted average shares 346 363 394 Potentially dilutive common stock equivalents stock options and other employee stock plans 8 12 Diluted weighted average shares 346 371 406 The dilutive effect of share-based awards is reflected in diluted net income (loss) per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation. The total number of share-based awards issued in 2009, 2008 and 2007 were 5 million, 10million and 16million, respectively. In connection with the October31, 2006 Verigy distribution, on November1, 2006 Agilent distributed .122435 of an ordinary share of Verigy for each outstanding share of Agilent common stock owned as of October16, 2006 to Agilent's stockholders. In addition, under the anti-dilution provision of the 1999 Stock Plan, on November1, 2006 Agilent adjusted the exercise price downward and number of option shares upward for each outstanding employee stock option to preserve the value of the options after the Verigy spin-off. For further details on the distribution see Note3, "Share-Based Compensation." The following table presents options to purchase shares of common stock, which were not included in the computation of diluted net income (loss) per share because they were anti-dilutive. Years Ended October 31, 2009 2008 2007 Options to purchase shares of common stock (in millions) 29 7 5 Weighted-average exercise price $30 $42 $47 Average common stock price $20 $33 $35

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Supplemental Cash Flow Information	6. SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for income taxes was $113 million in 2009, $210 million in 2008 and $86million in 2007. Cash paid for interest was $88 million in 2009 and 2008 and $89million in 2007.

INVENTORY

INVENTORY
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Inventory	7. INVENTORY October 31, 2009 2008 (in millions) Finished goods $285 $331 Purchased parts and fabricated assemblies 267 315 Inventory $552 $646 Inventory-related excess and obsolescence charges of $54million, $24 million and $21million were recorded in total cost of products in 2009, 2008 and 2007, respectively. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Property, Plant and Equipment, Net	8. PROPERTY, PLANT AND EQUIPMENT, NET October 31, 2009 2008 (in millions) Land $97 $91 Buildings and leasehold improvements 1,210 1,147 Machinery and equipment 779 758 Software 365 350 Total property, plant and equipment 2,451 2,346 Accumulated depreciation and amortization (1,606) (1,522) Property, plant and equipment, net $845 $824 Asset impairments other than restructuring were zero million in 2009 and $1 million in both 2008 and 2007. Depreciation expenses were $112 million in 2009, $126million in 2008 and $142million in 2007.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Goodwill and Other Intangible Assets	9. GOODWILL AND OTHER INTANGIBLE ASSETS The goodwill balances at October31, 2009 and 2008 and the movements in 2009 and 2008 for each of our reportable segments are shown in the table below: Electronic Measurement Bio-analytical Measurement Semicondutor Board Test Total (in millions) Goodwill at October31, 2007 $277 $237 $44 $558 Foreign currency translation impact 27 (1) (5) 21 Goodwill arising from acquisitions 25 42 67 Goodwill at October31, 2008 329 278 39 646 Foreign currency translation impact 19 1 6 26 Disposals (15) (7) (22) Goodwill arising from acquisitions 3 2 5 Goodwill at October31, 2009 $336 $274 $45 $655 The component parts of other intangible assets at October31, 2009 and 2008 are shown in the table below: Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2008: Purchased technology $281 $124 $157 Trademark/Tradename 32 3 29 Customer relationships 85 43 42 Total $398 $170 $228 As of October 31, 2009: Purchased technology $281 $170 $111 Trademark/Tradename 32 6 26 Customer relationships 85 55 30 Total $398 $231 $167 In 2009, we recorded $5 million of goodwill primarily relating to the purchase of the remaining unowned portion of a joint venture. Goodwill was reduced by $22 million due to businesses that we divested during 2009 some of which had not been fully integrated into Agilent. We recorded zero additions to other intangibles and recorded $16 million of impairment charges to other intangibles primarily related to divested businesses. In 2008, we purchased $103 million of other intangibles and recorded $67 million of goodwill relating to seven acquisitions and a purchase of the remaining unowned portion of a joint venture.On December 18, 2007, we completed the acquisition of Velocity 11, a designer, manufacturer and marketer of robotic solutions. The aggregate purchase price was approximately $111 million in cash used to purchase 100 percent of Velocity 11s outstanding common shares and vested common stock options that Velocity 11 employees held on the closing date of the acquisition. Pro forma disclosures were not required for any ofthese acquisitions, as they were not material. Amortization of intangible assets was $45 million in 2009, $53 million in 2008, and $40 million in 2007.Future amortization expense related to existing purchased intangible assets is estimated to be $39 million in 2010, $35 million for 2011, $28 million for 2012, $20 million for 2013, $14 million for 2014, and $31 million thereafter.

INVESTMENTS

INVESTMENTS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Investments	10. INVESTMENTS The following table summarizes the companys investments as of October 31, 2009 and 2008 (net book value): October 31, 2009 2008 (in millions) Short-Term Available-for-sale investments $14 $24 Long-Term Cost method investments $82 $68 Trading securities 50 57 Available-for-sale investments 31 81 Total $163 $206 Cost method investments consist of non-marketable equity securities and two special funds and are accounted for at historical cost. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings. Investments designated as available-for-sale are reported at fair value, with unrealized gains and losses, net of tax, included in stockholders' equity. In February 2008, Agilent traded an externally managed short-term investment fund for the underlying securities of the investment and now manages those investments internally. The securities received were fixed income debt securities and are held as available-for-sale. Agilent estimated the fair values based on quoted market prices or pricing models using current market rates. These estimated fair values may not be representative of actual values that could have been realized as of October 31, 2009 and 2008 or that will be realized in the future. Investments in available-for-sale securities at estimated fair value were as follows as of October 31, 2009 and October 31, 2008: October 31, 2009 October 31, 2008 Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value (in millions) Debt securities $36 $ $ $36 $101 $ $(5) $96 Equity securities 4 5 9 4 5 9 $40 $5 $ $45 $105 $5 $(5) $105 Contractual maturities of available-for-sale debt securities were as follows at October 31, 2009: Cost Estimated Fair Value (in millions) Due in less than 1 year $ 14 $ 14 Due in 1-5 years 6 7 Due after 5 years 16 15 $ 36 $ 36 All of our investments, excluding trading securities, are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have significant adverse effect on the future value of the investment. We consider various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, forecasted recovery, the financial condition and near-term prospects of the investee, and our ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. Amounts included in other income (expense) for realized gains and losses on the sale of available-for-sale securities and other than temporary impairments were as follows:

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Fair Value Measurements	11. FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2009 were as follows: Fair Value Measurementat October 31, 2009 Using October 31, 2009 QuotedPrices in Active Markets for IdenticalAssets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,888 $ 1,888 $ $ Available-for-sale investments 14 11 3 Derivative instruments 14 14 Long-term Trading securities 50 50 Available-for-sale investments 31 9 19 3 Restricted cash (commercial paper) 1,555 1,555 Total assets measured at fair value $ 3,552 $ 1,947 $ 1,599 $ 6 Liabilities: Short-term Derivative instruments $ 8 $ $ 8 $ Long-term Deferred compensation liability 49 49 Total liabilities measured at fair value $ 57 $ $ 57 $

DERIVATIVES

DERIVATIVES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Derivatives	12. DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of risk management strategy, we use derivative instruments, primarily forward contracts, purchased options, and interest rate swaps, to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates and interest rates. Fair Value Hedges The company enters into fair value hedges to reduce the exposure of our debt portfolio to interest rate risk. We issue long-term senior notes in U.S. dollars based on market conditions at the time of financing. We use interest rate swaps to modify the market risk exposure in connection with fixed interest rate senior notes to U.S. dollar London inter bank offered rate (LIBOR) -based floating interest rate. Alternatively, we may choose not to swap fixed for floating interest rate or may terminate a previously executed swap.We designate and qualify these interest rate swaps as fair value hedges of the interest rate risk inherent in the debt. For derivative instruments that are designated and qualify as fair value hedges, we recognize the gain or loss on the derivative instrument, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, in interest expense, in the consolidated statement of operations. The fair value of the swaps is recorded on the consolidated balance sheet at each period end, with an offsetting entry in senior notes. As of October 31, 2009, there were 9 interest rate swap contracts designated as fair value hedges. The notional amount of these interest rate swap contracts, receive-fixed/pay-variable, was $750 million. Cash Flow Hedges The company also enters into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance.The changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income. Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when either the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. Changes in the fair value of the ineffective portion of derivative instruments are recognized in cost of sales in the consolidated statement of operations in the current period. Other Hedges Additionally, the company enters into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the consolidated statement of ope

RESTRUCTURING COSTS, ASSET IMPA

RESTRUCTURING COSTS, ASSET IMPAIRMENTS AND OTHER SPECIAL CHARGES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Restructuring Costs, Asset Impairments And Special Charges	13. RESTRUCTURING COSTS, ASSET IMPAIRMENTS AND OTHER SPECIAL CHARGES Our 2005 restructuring program, announced in the fourth quarter of 2005, is largely complete. The remaining obligations under this and previous plans relate primarily to lease obligations that are expected to be satisfied over approximately the next two years. In the first quarter of 2009, we announced a new restructuring program (the "FY 2009 Plan) to reduce our annual operating expenses by reducing approximately 500 positions of the global workforce of regular employees. The FY 2009 Plan was conceived in response to deteriorating economic conditions and is designed to deliver sufficient savings to enable our businesses to reach their profitability targets. In the second quarter of 2009, we announced additional actions as part of the FY 2009 Plan to restructure our global infrastructure organization and our electronic measurement and semiconductor board test segments in response to the continuing deterioration of economic conditions. These additional actions will ultimately reduce our global workforce of regular employees by approximately 3,300 positions, bringing the total headcount reductions under the FY 2009 Plan to approximately 3,800 positions. We expect to complete all the actions under the FY 2009 Plan by the second quarter of fiscal 2010. As of October 31, 2009 approximately 600 employees within electronic measurement are pending termination under the FY 2009 Plan. Special charges related to inventory include estimated future payments that we are contractually obliged to make to our suppliers in connection with future inventory purchases and inventory on hand written down. In both cases, actions taken under our FY 2009 Plan, including exiting lines of business, have caused the value of this inventory to decrease below its cost. A summary of total restructuring activity and other special charges is shown in the table below: Workforce Reduction Consolidation of Excess Facilities Impairment of Building and Purchased Intangible Assets Special Charges related to Inventory Total (in millions) Balance as of October31, 2006 $13 $58 $ $ $71 Income statement expense 17 (5) 12 Cash payments (29) (22) (51) Balance as of October31, 2007 $1 $31 $ $ $32 Income statement expense (4) (4) Cash payments (1) (17) (18) Balance as of October31, 2008 $ $10 $ $ $10 Income statement expense 202 18 27 20 267 Asset impairments/inventory charges (27) (9) (36) Cash payments (153) (9) (10) (172) Balance as of October 31, 2009 $49 $19 $ $1 $69 The restructuring and other special accruals for all plans, which totaled $69 million at October 31, 2009 and $10million at October31, 2008, are recorded in other accrued liabilities and other long-term liabilities on the consolidated balance sheet. These balances reflect estimated future cash outlays. We expect workforce reduction payments, prim

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Retirement Plans and Post Retirement Pension Plans	14. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS General. Substantially all of our employees are covered under various defined benefit and/or defined contribution pension plans. Additionally, we sponsor post-retirement health care benefits and a death benefit under the Agilent Survivor Protection Plan for our eligible U.S. employees. Agilent provides U.S. employees, who meet eligibility criteria under the retirement plan, defined benefits which are generally based on an employee's highest five consecutive years' average pay during the years of employment and on length of service. For eligible service through October31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under our defined contribution Deferred Profit-Sharing Plan ("DPSP"), which was closed to new participants as of November1993. In addition, in the U.S., Agilent maintains the Supplemental Benefits Retirement Plan (SBRP), a supplemental non-qualified defined benefit plan to provide benefits that would be provided under the Retirement Plan (RP)but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the U.S. Plans. As of October31, 2009 and 2008, the fair value of plan assets of the DPSP for U.S. Agilent Employees was $517 million and $520million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets. Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. Our U.S. retirees who retired prior to January1, 2005, are also covered by a lump sum death benefit that is part of the Agilent Survivor Protection Plan. In July2004, the Agilent Survivor Protection Planwas revised to eliminate the $5,000 Retiree Survivor Benefit for all U.S. retirees who retire on or after January1, 2005. See also Plan Amendments below. 401(k) defined contribution plan.Eligible U.S. employees may participate in the Agilent Technologies,Inc. 401(k) Plan (the "401(k) Plan"). Enrollment in the 401(k) Plan is automatic for employees who meet eligibility requirements unless they decline participation. Under the 401(k) Plan, we provide matching contributions to employees up to a maximum of 4percent of an employee's annual eligible compensation. The maximum contribution to the 401(k) Plan is 50percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan expense included in income from operations was $23 million in 2009, $26million in 2008 and $25million in 2007Post-retirement medical benefit plans. In addition to receiving pension benefits, our U.S. employees who meet eligibility requirements as of their termination date may participate in our Non-Medicare Medical Plan, and if eligible, the Medicare Medical Plan under the Agilent Health Plan. These two plans are (the Post-Retirement Benefit Plans). Current U.S. employees may become eligible for these benefits, and the existing benefit obligat

GUARANTEES

GUARANTEES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Guarantees	15. GUARANTEES Standard Warranty A summary of the standard warranty accrual activity is shown in the table below. The standard warranty accrual balances are held in other accrued and other long-term liabilities. October 31, 2009 2008 (in millions) Balance as of October 31, 2008 and 2007 $ 29 $ 29 Accruals for warranties issued during the period 44 50 Changes in estimates 6 1 Settlements made during the period (51 ) (51 ) Balance as of October 31, 2009 and 2008 $ 28 $ 29 Indemnifications to Avago In connection with the sale of our semiconductor products business in December2005, we agreed to indemnify Avago, its affiliates and other related parties against certain damages that it might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to Avago, as well as pre-closing taxes and other specified items. In our opinion, the fair value of these indemnifications was not material as of October31, 2009. Indemnifications to Verigy In connection with the spin-off of Verigy, we agreed to indemnify Verigy and its affiliates against certain damages which it might incur in the future. These indemnifications primarily cover damages relating to liabilities of the businesses that Agilent did not transfer to Verigy, liabilities that might arise under limited portions of Verigy's IPO materials that relate to Agilent, and costs and expenses incurred by Agilent or Verigy to effect the IPO, arising out of the distribution of Agilent's remaining holding in Verigy ordinary shares to Agilent's stockholders, or incurred to effect the separation of the semiconductor test solutions business from Agilent to the extent incurred prior to the separation on June1, 2006. In our opinion, the fair value of these indemnifications was not material as of October31, 2009. Indemnifications to Hewlett-Packard We have given multiple indemnities to Hewlett-Packard in connection with our activities prior to our spin-off from HP for the businesses that constituted Agilent prior to the spin-off. These indemnifications cover a variety of aspects of our business, including, but not limited to, employee, tax, intellectual property and environmental matters. The agreements containing these indemnifications have been previously disclosed as exhibits to our registration statement on FormS-1 filed on August16, 1999. In our opinion, the fair value of these indemnifications was not material as of October31, 2009. Indemnifications to Officers and Directors Our corporate by-laws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Commitments and Contingencies	16. COMMITMENTS AND CONTINGENCIES Operating Lease Commitments: We lease certain real and personal property from unrelated third parties under non-cancelable operating leases. Future minimum lease payments under operating leases at October31, 2009 were $60 million for 2010, $51 million for 2011, $33million for 2012, $19 million for 2013, $14million for 2014 and $32 million thereafter. Future minimum sublease income under leases at October31, 2009 was $3 million for 2010, $2 million for 2011, $2 million for 2012, $1 million for 2013 and zero thereafter. Certain leases require us to pay property taxes, insurance and routine maintenance, and include escalation clauses. Total rent expense, including charges relating to the consolidation of excess facilities was $95 million in 2009, $89 million in 2008 and $73million in 2007. We are involved in lawsuits, claims, investigations and proceedings, including patent, commercial and environmental matters. There are no matters pending that we expect to be material in relation to our business, consolidated financial condition, results of operations or cash flows

SHORT TERM DEBT

SHORT TERM DEBT
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Short-Term Debt	17. SHORT-TERM DEBT On May 11, 2007, we entered into a five-year credit agreement, which provides for a $300 million unsecured credit facility that will expire on May 11, 2012. On September8, 2009, we entered into an Accession Agreement, increasing the credit facility from $300 million to $330 million. The company may use amounts borrowed under the facility for general corporate purposes. As of October 31, 2009 the company has no borrowings outstanding under the facility. On August 17, 2009 the credit agreement was amended to provide additional financing flexibility in advance of the pending acquisition of Varian, Inc.The amendment allows for up to $1 billion of additional indebtedness, incurred during the period from August 17, 2009 through the closing of the acquisition, to be excluded from the leverage ratio covenant until the later of the first day of the month following the ninth full calendar month after the closing of the acquisition or August 1, 2010; it also temporarily reduces the basket for other secured financing we are permitted to incur from $300 million to $75 million during this period. The amendment also increases by $500 million the amount of repurchase obligations (such as those of Agilent Technologies World Trade, Inc., a consolidated wholly-owned subsidiary of Agilent (World Trade) (see Note 19, Long-Term Debt and Long-Term Restricted Cash and Cash Equivalents)), that we are permittedto incur.

SENIOR NOTES

SENIOR NOTES
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Senior Notes	18. SENIOR NOTES The following table summarizes the companys senior notes: Years Ended October31, 2009 2008 (inmillions) 2017 Senior Notes $ 637 $ 611 2015 Senior Notes 500 - 2012 Senior Notes 251 - Total $ 1,388 $ 611 2017 Senior Notes In October2007, the company issued an aggregate principal amount of $600million in senior notes. The senior notes were issued at 99.60% of their principal amount. The notes will mature on November1, 2017, and bear interest at a fixed rate of 6.50% per annum. The interest is payable semi-annually on May1st and November1st of each year and payments commenced on May1, 2008. On November25, 2008, we terminated the two remaining interest rate swap contracts associated with our 2017 senior notes that represented the notional amount of $400million. The asset value upon termination was approximately $43million. The proceeds were recorded as operating cash flows and the gain is being deferred and amortized over the remaining life of the senior notes. 2015 Senior Notes In September2009, the company issued an aggregate principal amount of $500million in senior notes. The senior notes were issued at 99.69% of their principal amount. The notes will mature on September14, 2015, and bear interest at a fixed rate of 5.50% per annum. The interest is payable semi-annually on March14th and September14th of each year, payments commencing on March14, 2010. 2012 Senior Notes In September2009, the company also issued an aggregate principal amount of $250million in senior notes. The senior notes were issued at 99.91% of their principal amount. The notes will mature on September14, 2012, and bear interest at a fixed rate of 4.45% per annum. The interest is payable semi-annually on March14th and September14th of each year, payments commencing on March14, 2010. All notes issued are unsecured and rank equally in right of payment with all of Agilents other senior unsecured indebtedness. The company incurred issuance costs of $5 million in connection with the 2017 senior notes and a total of $5 million in connection with the 2015 and 2012 senior notes. These costs were capitalized in other assets on the consolidated balance sheet and the costs are being amortized to interest expense over the term of the senior notes. Upon the closing of the offering of the 2015 and 2012 senior notes, we entered into interest rate swaps with an aggregate notional amount of $750 million. Under the interest rate swaps, we will receive fixed-rate interest payments and will make payments based on the U.S. dollar LIBOR plus 253 basis points and 257.6 basis points with respect to the 2015 and 2012 senior notes, respectively. The economic effect of these swaps will be to convert the fixed-rate interest expense on the senior notes to a variable LIBOR-based interest rate. In addition, as a result of the fair value hedge, the senior notes are presented on our balance sheet at fair value, reflecting the change in their value attributable to interest rate risk. The hedging relationship qualifies for the shortcut method of assessing hedge effectiven

LONG TERM DEBT AND LONG TERM RE

LONG TERM DEBT AND LONG TERM RESTRICTED CASH AND CASH EQUIVALENTS
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Long-Term Debt And Long-Term Restricted Cash And Cash Equivalents	19.LONG-TERM DEBT AND LONG-TERM RESTRICTED CASH CASH EQUIVALENTS The following table summarizes the companys long-term debt: Years Ended October31, 2009 2008 (in millions) World Trade debt $ 1,500 $ 1,500 Other debt 16 14 Total long-term debt $ 1,516 $ 1,514 World Trade Debt In January 2006, World Trade entered into a five-year Master Repurchase Agreement with a counterparty in which World Trade sold 15,000 Class A preferred shares of Agilent Technologies (Cayco) Limited (Cayco) to the counterparty, having an aggregate liquidation preference of $1.5 billion. World Trade owns all of the outstanding common shares of Cayco, a separate legal entity. In September 2008, Agilent and World Trade entered into an agreement (the Lloyds Related Agreement) with Lloyds TSB Bank plc (Lloyds). Under the Lloyds Related Agreement, on November 17, 2008 (the Effective Date), Lloyds accepted the transfer by novation of all of the rights and obligations of the counterparty under a revised Master Repurchase Agreement. On the Effective Date, Lloyds paid $1.5 billion to the prior counterparty in consideration of the novation and World Trades repurchase obligation was extended to January 27, 2011 (the Extended Repurchase Date). World Trade is obligated to make aggregate quarterly payments to Lloyds at a rate per annum, reset quarterly, with reference to LIBOR plus 175 basis points beginning on the Effective Date. Lloyds can accelerate the Extended Repurchase Date or cause a redemption of the preferred Cayco shares only upon certain events of default, but neither World Trade nor Agilent has the right to accelerate the Extended Repurchase Date. The World Trade obligation of $1.5 billion is recorded and classified as a long-term debt on our consolidated balance sheet. Other Debt On August 11, 2008 a consolidated wholly-owned subsidiary of Agilent, borrowed Indian Rupees equivalent to $15 million from Citibank N.A. at 12.75 percent per annum interest rate for 5 years, maturing on August 9, 2013 to finance a capital project in India. The loan is recorded and classified as long-term debt on our consolidated balance sheet. Long-Term Restricted Cash Cash Equivalents As of October 31, 2009 and October 31, 2008, $1,566 million and $1,582 million were reported as long-term restricted cash and cash equivalents in our consolidated balance sheet, respectively. Of these amounts, $1,555 million and $1,571 million were held in commercial paper maintained in connection with our World Trade debt obligation as of October 31, 2009 and October 31, 2008, respectively.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Stock Repurchase Program	20. STOCK REPURCHASE PROGRAM As of October 31, 2009, our Board of Directors authorized stock repurchase programs of up to $8.466billion of our common stock. As of October 31, 2009, we had repurchased a total of approximately 220million shares of our common stock for $7.624billion. In addition, $3 million of service and legal fees were recorded in equity. All such shares and related costs are held as treasury stock and accounted for using the cost method. The remaining amount that is authorized under the 2008 program is $843 million. On March26, 2009, the company announced that it was suspending its stock repurchase program until the end of the 2009 fiscal year. On November15, 2009, the companys 2008 stock repurchase program expired upon the termination of its two-year term (see note 22 Subsequent Event). Share Repurchase Programs Number of Shares Repurchased Amount of Shares Repurchased (in millions) Fiscal Year 2005 Program 125 $ 4,466 Fiscal Year 2006 Program 56 $ 2,000 Fiscal Year 2008 Program Balance as of October 31, 2008 30 $ 1,001 Repurchases in 2009 9 157 Total for Fiscal Year 2008 Program 39 $ 1,158 Total 220 $ 7,624

SEGMENT INFORMATION

SEGMENT INFORMATION
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Segment Information	21. SEGMENT INFORMATION Description of segments.We are a measurement company, providing core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. Agilent has three businesses bio-analytical measurement, electronic measurementand semi-conductor and board test each of which comprises a reportable segment. In the beginning of the first fiscal quarter of 2009, we formed a new operating segment from our existing businesses: the semiconductor and board test segment. The new segment covers semiconductor equipment and services sold to semiconductor manufacturing and printer circuit board assembly customers. In addition, in the first quarter of 2009, we moved microscopy measurement from the bio-analytical measurement segment to the electronic measurement segment. All historical segment numbers have been recast to conform to this new reporting structure in our financial statements The segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Other factors, including customer base, homogeneity of products, technology and delivery channels, were also considered in determining our reportable segments. A description of our three reportable segments is as follows: Bio-analytical measurement business provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Our key product categories include: gas chromatography, liquid chromatography, mass spectrometry, inductively coupled plasma mass spectroscopy, microfluidics, electrophoresis, microarrays,PCR (Polymerase Chain Reaction) instrumentation, laboratory automation and robotics, software and informatics, and related bioreagents, consumables and services. Electronic measurement business provides standard and customized electronic measurement instruments and systems, monitoring, management and optimization tools for communications networks and services, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and communications networks and services. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. We also offer customization, consulting and optimization services throughout the customers product lifecycle. Semiconductor and board test business provides standard and customized measurement instruments and systems which enable customers to develop and test state of the art semiconductors, test and inspect printed circuit boards, perform functional testing, and measure position and distance information to the sub-nanometer level. A significant portion of the segments expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges

SUBSEQUENT EVENT

SUBSEQUENT EVENT
	12 Months Ended Oct. 31, 2009 USD / shares
Notes To Financial Statements [Abstract]
Subsequent Event	22. SUBSEQUENT EVENT We evaluated all events or transactions that occurred after October 31, 2009 and up to December 21, 2009, the date we issued these financial statements. On November 19, 2009 our Board of Directors approved a new share-repurchase program to reduce or eliminate dilution in connection with issuances of stock under the companys equity incentive plans. The new sharerepurchase program does not require the company to acquire a specific number of shares and may be suspended or discontinued at any time. There is no fixed termination date for the new share-repurchase program.

Document Information

Document Information
	12 Months Ended Oct. 31, 2009 USD / shares
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	2009-10-31

Entity Information

Entity Information (USD $)
	12 Months Ended Oct. 31, 2009	Nov. 30, 2009	Apr. 30, 2009
Entity Information [Line Items]
Entity Registrant Name	AGILENT TECHNOLOGIES INC
Entity Central Index Key	0001090872
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$5,753,000,000
Entity Common Stock, Shares Outstanding		348,831,278